Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KYNU | Q16719 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873181 | 0.84 | KLK5 (0.46) | KLK5SYKALDH1A1ALOX15KYNU | |
| SCHEMBL4798047 | 0.83 | SYK (0.47) | KLK5SYKALDH1A1ALOX15KYNU | |
| SCHEMBL5103254 | 0.83 | SYK (0.46) | KLK5SYKALDH1A1ALOX15KYNU | |
| SCHEMBL2212805 | 0.80 | KLK5 (0.48) | KLK5SYKALDH1A1ALOX15KYNU | |
| SCHEMBL2212808 | 0.80 | KLK5 (0.48) | KLK5SYKALDH1A1ALOX15KYNU | |
| SCHEMBL5161761 | 0.79 | KLK5 (0.52) | KLK5SYKALDH1A1ALOX15KYNU | |
| SCHEMBL2213620 | 0.79 | SYK (0.47) | KLK5SYKALDH1A1ALOX15KYNU | |
| SCHEMBL2214215 | 0.79 | SYK (0.47) | KLK5SYKALDH1A1ALOX15KYNU | |
| SCHEMBL2209833 | 0.79 | SYK (0.46) | KLK5SYKALDH1A1ALOX15KYNU | |
| SCHEMBL2209830 | 0.79 | SYK (0.46) | KLK5SYKALDH1A1ALOX15KYNU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368458-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368458-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368458-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2006076597-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060155126-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155126-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | KLK5 4528/4885SYK 2138/4885ALDH1A1 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.